Antitumor effect of siRNA on endometrial cancer

siRNA对子宫内膜癌的抗肿瘤作用

• 批准号: 21791573
• 负责人: YANOKURA Megumi
• 金额: $ 4.08万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21791573/
• 关键词: siRNA; 子宮体癌; 分子イメージング; CHFR; タキサン製剤; Aurora-A; in vivoイメージング

Tumor development occurred 3 weeks after transplantation of HEC-1B cells in nude mice. Drugs were administered on that day and thereafter. The tumor diameter significantly decreased in mice treated with paclitaxel+Aurora-A siRNA compared with the results for other treatments(P<0. 05). The GFP fluorescence signal also markedly decreased after treatment with paclitaxel+Aurora-A siRNA.Aurora-A siRNA may have the potential to increase the sensitivity of endometrial tumors to treatment with paclitaxel.

HEC-1B细胞移植到裸鼠体内3周后，肿瘤发生。当日及此后给予药物。紫杉醇+Aurora-A siRNA治疗组小鼠肿瘤直径较其他治疗组明显减小(P<0. 05)。紫杉醇+Aurora-A siRNA治疗后GFP荧光信号也显着降低。Aurora-A siRNA可能具有增加子宫内膜肿瘤对紫杉醇治疗的敏感性的潜力。